

---

## View Now | CP-RND: An Introduction to the Patient Community

Hosted by the C-Path team, you can [view this recorded webinar](#) to learn more about the Critical Path for Rare Neurodegenerative Diseases public-private partnership.

This webinar and patient-focused roundtable will deliver an enhanced understanding of:

- The CP-RND strategic plan, its stakeholder groups and program deliverables
- The envisioned impact of CP-RND on medical product development in rare neurodegenerative diseases
- Perspectives from patients, regulators and the industry on the public-private partnership and the rare neurodegenerative disease community

Speakers and panelists included:



**Ronald J. Bartek**  
Co-founder/President,  
Friedreich's Ataxia Research  
Alliance



**Lauren Boak, PhD**  
Lifecycle Leader, GPS NSRD,  
Roche



**Michelle Campbell, PhD**  
Associate Director, Stakeholder  
Engagement and Clinical  
Outcomes, U.S. Food and Drug  
Administration



**Jacqueline Corrigan-Curay, JD,  
MD**  
Principal Deputy Center Director,  
Center for Drug Evaluation and  
Research, U.S. Food and Drug  
Administration



**Philip Green**  
ALS Patient Advocate



**Collin Hovinga, PharmD, MS,  
FCCP**  
Vice President of the Rare and  
Orphan Disease Programs,  
Critical Path Institute



**Walter Koroshetz, MD**  
Director, National Institute of  
Neurological Disorders and  
Stroke



**Terina N. Martinez, PhD**  
Executive Director, Critical Path  
for Rare Neurodegenerative  
Diseases, Critical Path Institute



**Klaus Romero, MD, MS,  
FCCP**  
Chief Science Officer;  
Executive Director of Clinical  
Pharmacology, Critical Path  
Institute



**Celia Witten, MD, PhD**  
Deputy Director, Center for  
Biologics Evaluation and  
Research, U.S. Food and Drug  
Administration